MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

Search

Adverum Biotechnologies Inc

Gesloten

SectorGezondheidszorg

4.3

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+11.93% upside

Nieuwssentiment

By Acuity

50%

50%

149 / 374 Rangschikking in Healthcare

Adverum Biotechnologies Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 okt 2025, 13:04 UTC

Acquisities, Fusies, Overnames

Eli Lilly Agrees to Acquire Adverum Biotechnologies

9 dec 2025, 13:32 UTC

Acquisities, Fusies, Overnames

Eli Lilly: Parties Expect to Consummate the Acquisition on Dec 9 >LLY

9 dec 2025, 13:32 UTC

Acquisities, Fusies, Overnames

Lilly and Purchaser Accepted for Payment, and Will Promptly Pay, for All Shrs

9 dec 2025, 13:29 UTC

Acquisities, Fusies, Overnames

Lilly and Adverum Announce Expiration and Completion of Adverum Tender Offer and Acquisition

24 okt 2025, 12:34 UTC

Acquisities, Fusies, Overnames

Eli Lilly Says Transaction Is Expected to Close in the 4Q >LLY

24 okt 2025, 12:34 UTC

Acquisities, Fusies, Overnames

Eli Lilly: Offer Also Includes 1 Non-Transferrable Contingent Value Right Entitling Holder to Receive Up to an Additional $8.91 Per CVR in Cash Upon the Achievement of 2 Milestones, for Total Potential Consideration of Up to $12.47/Shr >LLY

24 okt 2025, 12:33 UTC

Acquisities, Fusies, Overnames

Eli Lilly to Launch Tender Offer to Acquire All Outstanding Shares of Adverum for $3.56/Shr >LLY

24 okt 2025, 12:30 UTC

Acquisities, Fusies, Overnames

Lilly To Acquire Adverum Biotechnologies >LLY ADVM

Peer Vergelijking

Prijswijziging

Adverum Biotechnologies Inc Prognose

Koersdoel

By TipRanks

11.93% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.88Ā USDĀ  11.93%

Hoogste 5.5Ā USD

Laagste 4Ā USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Adverum Biotechnologies Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Sentiment

By Acuity

149 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

$

help-icon Live chat